Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | DTYMK | P23919 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2370137 | 0.90 | KDM4E (0.39) | KDM4ESMN1; SMN2MAPTPOLBBRD4 | |
| SCHEMBL6857665 | 0.81 | NAMPT (0.34) | KDM4ESMN1; SMN2MAPTKAT2BMAPK1 | |
| SCHEMBL2453838 | 0.74 | KDM4E (0.38) | KDM4ESMN1; SMN2MAPTBRD4KAT2B | |
| SCHEMBL6857387 | 0.74 | KDM4E (0.34) | KDM4ESMN1; SMN2MAPTMAPK1NPSR1 | |
| SCHEMBL2453240 | 0.73 | KDM5A (0.34) | KDM4ESMN1; SMN2MAPTBRD4KAT2B | |
| SCHEMBL22195274 | 0.70 | MEN1 (0.35) | KDM4EBRD4 | |
| SCHEMBL2381471 | 0.69 | NAMPT (0.33) | — | |
| SCHEMBL2369631 | 0.66 | KDM5A (0.40) | KDM4ESMN1; SMN2POLB | |
| SCHEMBL2370142 | 0.65 | CALCA (0.36) | KDM4ESMN1; SMN2MAPTPOLBBRD4 | |
| SCHEMBL2370205 | 0.65 | TDP1 (0.34) | KDM4ESMN1; SMN2MAPTPOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190499-A1 | Azaisoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-07-25 | — | — | US | disclosed |
| US-20110224247-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224247-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, KCND3 | KDM4E 1390/4885SMN1; SMN2 3378/4885MAPT 2678/4885 |
| US-20130190499-A1 | Azaisoquinolinone derivatives as NK3 antagonists | KCNQ3, KCNK3, KCND3 | KDM4E 1390/4885SMN1; SMN2 3378/4885MAPT 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.